Method for preparing less-immunogenic protein-lipid complexes

A novel method has been developed for preparing less immunogenic protein formulations. One composition derived from this method has demonstrated promising results in the delivery and efficacy of protein therapeutics (Factor VIII) involved in hemophi lia. By shielding the most immunogenic portion of the Factor VIII protein, UB researchers have created a complex that exhibits improved pharmaceutical properties. This technology can be applied to virtually any protein or peptide therapeutic includin g replacement therapies such as factor VIII and interferon-beta.

This technology offers a number of advantages:
* Ability of the protein (Factor VIII) to retain its activity even in the complexed form.
* Clotting activity is maintained eve n in the presence of inhibitors.
* Abatement of inhibitor development
* Increased stability and reduced aggregation
* Reduced antigenicity as demonstrated in ELISA assays.
* Eliminate the need for protein additives such as albumin< * Reduced immunogenicity as shown in animal models, which may potentially:
* Limit or potentially eliminate the need to switch formulations and/or undergo Immune Tolerance Therapy
* Reduce the frequency of administration and lo wer overall healthcare costs

Categories: Therapeutic and Vaccines

Commercialization Manager: STOR Intellectual Property Division Tel: 716-645-5500 Fax: 716-645-3436 Email: [email protected]

Patents Issues: 7,351,688

Patents:
US 7,351,688

Type of Offer: Licensing



« More Pharmaceutical Patents
« More Medical Patents

---